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ABSTRACT
Nucleases play important roles in DNA synthesis,
recombination and repair. We have previously
shown that human exonuclease 1 (hEXO1) is phos-
phorylated in response to agents stalling DNA
replication and that hEXO1 consequently undergoes
ubiquitination and degradation in a proteasome-
dependent manner. In the present study, we have
addressed the identity of the pathway transducing
stalled-replication signals to hEXO1. Using chemical
inhibitors, RNA interference, ATM- and ATR-defi-
cient cell lines we have concluded that hEXO1
phosphorylation is ATR-dependent. By means of
mass spectrometry, we have identified the sites of
phosphorylation in hEXO1 in undamaged cells and
in cells treated with hydroxyurea (HU). hEXO1 is
phosphorylated at nine basal sites and three addi-
tional sites are induced by HU treatment. Analysis of
single- and multiple-point mutants revealed that
mutation to Ala of the three HU-induced sites of
phosphorylation partially rescued HU-dependent
degradation of hEXO1 and additionally stabilized
the protein in non-treated cells. We have raised an
antibody to pS714, an HU-induced site of the S/T-Q
type, and we provide evidence that S714 is phos-
phorylated upon HU but not IR treatment. The
antibody may be a useful tool to monitor signal
transduction events triggered by stalled DNA
replication.
INTRODUCTION
Exonuclease 1 is a DNA repair nuclease of the Rad2
family originally identiﬁed in the ﬁssion yeast
Schizosaccharomyces pombe (1). The activity of S. pombe
Exo1 gene product is induced about 5-fold just prior to
meiosis, which led to the suggestion that Exo1 might be
involved in meiotic homologous recombination (1).
Transcriptional induction of the Saccharomyces cerevisiae
and the Drosophila melanogaster EXO1 gene during
meiosis has also been reported (2,3). Mouse Exo1 was
found predominantly expressed in testis and the spleen,
consistent with roles in processes speciﬁc to germ cell
maturation and hematopoiesis (4). The human homolog
EXO1 gene encodes a protein bearing only 27% identity
to its yeast counterpart (5,6). Nonetheless, human
exonuclease 1 (hEXO1) was shown to be functionally
similar to the yeast protein by its ability to complement
S. cerevisiae Exo1 and the mutator phenotype of the yeast
rad27 mutant (5,7). In humans, two isoforms (hEXO1a
and hEXO1b) have been described to arise from
alternative splicing (5,8), though no functional diﬀerences
between the two isoforms have been reported. The
expression of hEXO1 reﬂects the pattern reported for
the mouse, with high levels in testis, thymus and colon and
slightly lower expression in small intestine, placenta,
spleen and ovary (5).
EXO1 catalyzes the removal of mononucleotides
from the 50 end of the DNA duplex, showing a strong
preference for blunt-ended, 50 recessed termini and DNA
nicks. It can also degrade exonucleolytically single-
stranded DNA, although less eﬃciently than double-
stranded DNA (9,10). Moreover, hEXO1 displays
a5 0 ssDNA-ﬂap-speciﬁc endonuclease activity but
does not possess endonuclease activity at bubble-like
structures (10).
In S. cerevisiae, EXO1 was shown to participate in
meiotic crossing over as well as in the processing of
double-strand breaks (DSB) ends (2). An additional
role in mutation avoidance and mismatch correction was
described for S. pombe Exo1 (11). Mismatch repair
(MMR) is a mechanism reducing the rate of somatic
microsatellite polymorphism and it is disabled in a
number of human cancers (12). The involvement of
Exo1 in MMR was conﬁrmed by studies demonstrating
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the MMR proteins Msh2 (6) and Mlh1 (13). Furthermore,
an independent study conﬁrmed the structural role of
yeast Exo1 in the stabilization of the multiprotein complex
containing MMR proteins (14). Studies conducted with
human recombinant proteins or HeLa cells extracts con-
ﬁrmed the interaction between hEXO1 and the MMR
proteins hMSH2 (15) and hMLH1/hPMS2 (16). The
functional role of hEXO1 in MMR was addressed in
complementation assays (5) as well as in reconstituted
systems (17–20). Taken together, the evidence provided by
these studies pointed to hEXO1 as the most likely
candidate for the excision step during MMR in mammals.
In addition to MMR, yeast Exo1 was shown to participate
to mitotic (21) and meiotic recombination (2) and to
end-resection at telomeres (22). The physical interaction
observed in human cells between hEXO1 and the Werner
Syndrome helicase WRN (23) and RECQ1 (24) further
pointed to a role for hEXO1 in the resolution of DNA
intermediates that are formed during recombination (25).
In ectopic expression studies, hEXO1 was shown to inter-
act with PCNA via its C-terminal region and the two
proteins co-localized at DNA replication foci (26). Proper
nuclear localization of hEXO was shown to depend on
the sequence K418RPR421, which exhibits strong homol-
ogy to other monopartite nuclear localization sequences
(NLS) (27).
The importance of exonuclease 1 is underscored by the
phenotype of Exo1
 /  mice that displayed reduced
survival, sterility and increased susceptibility to the
development of lymphomas (28). Analysis of Exo1
 / 
cells revealed speciﬁc defects in MMR leading to elevated
microsatellite instability, increased mutation rate at the
Hprt locus and abnormal spindle structures in metaphase
cells (28). Moreover, Exo1 mutant mice displayed altered
somatic hypermutation and reduced class switch recombi-
nation (29).
Consistent with its proposed role at sites of DNA
replication (30,31), we have previously shown that the
hEXO1 protein is selectively destabilized in response to
fork arrest. We reported the rapid degradation of hEXO1
to depend on ubiquitin-mediated proteasome pathways
and to be facilitated by phosphorylation (32). In the
present study, we have examined the pathway transducing
the fork-arrest signal to hEXO1 and we have identiﬁed
ATR as the responsible kinase. Moreover, we have
localized the sites of phosphorylation in hEXO1 and
assessed their role in the stability of the protein. Finally,
we have generated and characterized an antibody to one
of the fork arrest-induced sites of phosphorylation in
hEXO1 that would represent a useful tool in studies
addressing DNA replication fork stalling.
MATERIALS AND METHODS
Antibodies and chemicals
The polyclonal antibody F-15 to the N-terminus of
hEXO1 was previously described (32). A monoclonal
antibody to full-length EXO1 (Ab-4, clone 266) was
purchased from NeoMarkers (Fremont, CA, USA).
Antibodies to CHK1-pS345, CHK2-pT68 and p53-pS15
were from Cell Signaling Technology (Beverly, MA,
USA). The antibody to ATM-pS1981 was from Rockland
(Gilbertsville, PA, USA). Antibodies to ATM and ATR
were from Gentex (San Antonio, TX, USA) and
Calbiochem (San Diego, CA, USA), respectively. Anti-
bodies to TFIIH (sc-293) and MSH6 (clone 44, G70220)
were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and BD Transduction Laboratories (San Jose, CA,
USA), respectively. The Omni-probe antibody (sc-499)
used to detect Omni-tagged hEXO1 was from Santa
Cruz Biotechnology. HRP-conjugated anti-mouse and
anti-rabbit secondary antibodies were obtained from
Amersham-Biosciences/GE-Healthcare (Otelﬁngen, Swit-
zerland), whereas the secondary anti-goat was obtained
from Santa Cruz Biotechnology.
The antibody to phosphorylated S714 in hEXO1 was
raised using the peptide CNIKLLDpSQSDQT, where
pS represents phospho-Serine (Eurogentec, Seraing,
Belgium). The HPLC puriﬁed peptide was coupled to
Keyhole Limpet Hemocyanin (KLH) and used to
immunize two rabbits. The resulting sera were aﬃnity
puriﬁed by two consecutive chromatography steps over
phosphopeptide and non-phosphopeptide columns. The
phospho-speciﬁc antibody was eluted with 0.1M glycine–
HCl pH 2.5 and neutralized with 1M Tris–HCl pH 8.0.
Hydroxyurea (HU) and caﬀeine were obtained from
Sigma (St. Louis, MO, USA) and dissolved in water.
KU-55933 was kindly provided by Kudos Pharmaceuti-
cals (Cambridge, UK) and dissolved in DMSO. MG132
was purchased from Calbiochem and dissolved in DMSO.
Expression vectorsfor wild type(wt) and mutant hEXO1
The protein referred as hEXO1 throughout this study
is the isoform b. An expression vector for wt-hEXO1
was created by subcloning full-length hEXO1 in
pcDNA3.1-His
 (Invitrogen, Carlsbad, CA, USA) 30 to
a His-tag that is speciﬁcally recognized by the Omni-probe
antibody. Single- and multiple-hEXO1 mutants of the
sites of phosphorylation (Ser/Thr>Ala) were generated
with the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) using wt-hEXO1 as
template. The overlapping oligonucleotides employed
were the following:
S454>A forward: 50-GCAATAAATCATTGGCCTT
TTCTGAAGTG-30
S454>A reverse: 50-CACTTCAGAAAAGCCCAATG
ATTTATTGC-30
T621>A forward: 50-GAGATTTTTCAAGAGCGCC
GAGCCCCTCTCC-30
T621>A reverse: 50-GGAGAGGGGCTCGGCGCTC
TTGAAAAATCTC-30
S714>forward: 50-GCAATATTAAGTTACTTGACG
ATCAAAGTGACCAGACC-30
S714>reverse: 50-CGTTATAATTCAATGAACTGCT
AGTTTCACTGGTCTGG-30
S674>A forward: 50-GGCATGTTCTGCACAGTCC
CAGGAAAG-30
S674>A reverse: 50-CTTTCCTGGGACTGTGCAGA
ACATGCC-30
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AAGTGG-30
S676>A reverse: 50-CCACTTTCCTGGGCCTGTGA
AGAAC-30
S693>A forward: 50-GCATCAAAGCTTGCTCAGTG
CTCTAG-30
S693>A reverse: 50-CTAGAGCACTGAGCAAGCTT
TGATGC-30
All single and multiple mutations were veriﬁed by DNA
sequencing.
Cell cultureand transfections
HEK-293, HEK-293T, HeLa, U2OS, mouse embryonal
ﬁbroblast (MEF) and NIH3T3 cells were maintained in
DMEM (OmniLab, Mettmenstetten, Switzerland) supple-
mented with 10% fetal calf serum (FCS) (Life technolo-
gies, Rockville, MD, USA), penicillin (100U/ml) and
streptomycin (100mg/ml). The ATM-deﬁcient (AT) ﬁbro-
blasts AT22IJE-T and the matched line complemented
with an ATM minigene (AT+ATM) were kindly
provided by Y. Shiloh (Tel Aviv University, Israel) and
were maintained as described (33). ATR-Seckel cells were
kindly provided by M. O’Driscoll and P. Jeggo
(University of Sussex, UK) and were maintained in
RPMI (OmniLab, Mettmenstetten, Switzerland) supple-
mented with 15% FCS, penicillin (100 units/ml) and
streptomycin (100mg/ml).
Transient transfections were performed in 6cm cell
culture dishes using 0.5mg expression vector for wt-EXO1
or Ala-point mutants and the FuGENE-6 transfection
reagent (Roche, Basel, Switzerland). Eight hours upon
transfection cells were either left untreated or treated with
HU for 24h and harvested 32h post-transfection.
To create stable cell lines expressing shRNA for ATM
or ATR, the constructs described in Ref. (34) were used.
HEK-293T cells were transfected either with empty vector
(EV) or with shRNA speciﬁc to ATM or ATR. Cells
underwent selection with 10mg/ml puromycin for 3 weeks.
Downregulation of speciﬁc target genes was monitored by
western blot analysis.
Irradiation of cell was performed using a Faxitron
Cabinet X-ray system, model 43855D (Faxitron X-ray
Corp., Wheeling, IL, USA).
Western blotting andimmunoprecipitation
Cellular proteins were extracted using ice-cold lysis buﬀer
(50mM Tris–HCl pH 7.5, 120mM NaCl, 20mM NaF,
1mM EDTA, 6mM EGTA, 15mM Na-pyrophosphate,
0.5mM Na-orthovanadate, 1mM benzamidine, 0.1mM
phenylmethylsulfonyl ﬂuoride and 1% nonidet P-40).
Protein concentration was determined using the Bio-Rad
Protein Assay Reagent (Bio-Rad, Hercules, CA, USA).
Detection of proteins by western blot analysis was
performed following separation of whole cell extracts
(50mg) on 8% SDS–PAGE. To detect ATM or ATR in
whole cell extracts, 6% SDS–PAGE was used. Proteins
were transferred to polyvinylidene diﬂuoride (PVDF)
(Amersham Biosciences GE-Healthcare, Otelﬁngen,
Switzerland), probed with appropriate antibodies and
immune complexes were revealed using the enhanced
chemiluminescence system (Amersham Biosciences
GE-Healthcare, Otelﬁngen, Switzerland).
Immunoprecipitation of hEXO1 was carried out with
polyclonal antibody F-15, as previously described (32),
using HEK-293 (2mg), HEK-293T (2mg), HeLa (5mg),
U2OS (7mg), MEF (6mg) or NIH3T3 (9mg) total cell
extracts. The immunoprecipitated proteins were revealed
by western blot using monoclonal Ab-4 antibody.
Massspectrometric analysis
HEK-293 cells were transfected with an expression vector
for wt-hEXO1 using Metafectene (Biontex, Planegg,
Germany) as transfection reagent. Twenty-four hours
upon transfection, cells were either left untreated or
treated with HU for 24h and were harvested 48h post-
transfection. Using the Omni-probe antibody, hEXO1 was
immunoprecipitated from 12mg of cell extracts, for 3h at
48C. The antibody was captured on protein G-agarose
beads that were subsequently washed twice with TNET
buﬀer (50mM Tris–HCl pH 7.5, 140mM NaCl, 5mM
EDTA and 1% Triton X-100) and twice with TNE buﬀer
(50mM Tris–HCl pH 7.5, 140mM NaCl and 5mM
EDTA) before boiling in an equal volume of 2 
Laemmli-SDS sample buﬀer. Samples were alkylated
with iodoacetamide (55mM) for 45min in the dark.
Proteins were subjected to electrophoresis on 8% SDS–
PAGE and stained with Coomasie Brilliant Blue. Bands
corresponding to Omni-hEXO1 were excised and digested
with 1mg trypsin (Promega, Madison, WI, USA) in
50mM ammonium bicarbonate (pH 8.0) at 378C for
16h (35). The resulting peptides were analyzed by
capillary liquid chromatography-tandem mass spectro-
metry (LC–MS/MS) using a Magic C18 100mm 10cm
HPLC column (Spectronex, Basel, Switzerland) connected
online to an ion-trap Finnigan DecaXP (ThermoFinnigan,
San Jose, CA, USA). A linear gradient from 5 to 50%
solvent B (0.1% formic acid and 80% (v/v) acetonitrile in
water) in solvent A (0.1% formic acid and 2% acetonitrile
in water) was delivered in 60min with a Rheos 2000
HPLC system (Flux, Basel, Switzerland) at 100ml/min
ﬂow rate. A pre-column ﬂow-splitter reduced the ﬂow to
 300nl/min and the peptides were manually loaded with a
10ml Hamilton syringe on a peptide cap-trap cartridge
(Michrom BioResources, Auburn, CA, USA) mounted in
the injection loop of the MS. The eluting peptides were
ionized by electrospray ionization, detected and the
peptide ions were automatically selected and fragmented
by collision-induced dissociation (MS/MS) in the ion trap.
Individual MS/MS spectra were compared against the
known protein sequence using TurboSequest software
(36). Phosphorylated peptides were sequenced more
than once.
RESULTS AND DISCUSSION
hEXO1 isphosphorylatedin response tofork arrest
Using HEK-293T cells as model system, we have pre-
viously shown that the hEXO1 protein is phosphorylated
and that inhibitors of DNA replication, but not genotoxic
agents, increase the extent of hEXO1 phosphorylation.
Nucleic Acids Research,2008, Vol. 36,No. 2 513This, in turn, results in ubiquitination of hEXO1, which is
followed by rapid degradation of the protein in a
proteasome-dependent manner (32). To assess whether
this is a peculiarity of HEK-293T cells or a common
response to agent that stall replication, we analyzed the
parental HEK-293 cells along with HeLa, U2OS, MEF
and NIH3T3 cells. In all cases, visualization of hEXO1
required immunoprecipitation, as the amount of hEXO1
protein present in total extracts was below the threshold of
detection of western blot analysis. This conﬁrmed that
hEXO1 is a rare protein in all cell lines examined.
Moreover, in all cases treatment with HU led to decrease
of hEXO1 protein amount (Figure 1A and Supplementary
Figure 1A), as previously reported for HEK-293T cells
(32). In order to identify the DNA structure checkpoint
pathway that controls phosphorylation of hEXO1, we
employed the non-selective PI3K-like kinase inhibitor
caﬀeine as well as the selective ATM inhibitor KU-55933
(37). Addition of caﬀeine to HEK-293T cells prior to the
treatment with HU abolished activation of the ATR-
downstream targetCHK1 andled torescue ofHU-induced
hEXO1 degradation (Figure 1B, compare lane 4 with lane
5). This, however, was not the case when cells were pre-
treated with the selective ATM inhibitor KU-55933
(Figure 1B, compare lane 4 with lane 6). In order to
assess whether KU-55933 was functional under our assay
conditions, we treated HEK-293T cells with the compound
prior to administering ionizing radiation (10Gy) or HU
(2mM). The data showed that whereas KU-55933 was
very eﬀective in inhibiting ATM phosphorylation at S1981
as well phosphorylation of the downstream eﬀector p53at
S15 in response to IR, the inhibitor could not block either
of the two events in cells treated with HU (Supplementary
Figure 1B). This indicates that the kinase activated in
response to HU was ATR. The ATR-dependent phos-
phorylation of ATM that we observed is in agreement with
evidence previously reported in the literature for
UV-induced DNA damage (38) and conﬁrms the reported
cross-talk between these two PI3K-like kinases (39). To
substantiate the ﬁnding that ATR controls hEXO1
stability, we examined the eﬀect of down-regulating ATR
or ATM by means of RNA interference. The shRNA
constructs employed (34) led to a speciﬁc, although not
compete, reduction of the level of the two PI3K-like
kinases (Figure 1C). In this setting, the HU-induced
hEXO1 degradation was only rescued upon knocking-
down ATR expression. The residual hEXO1 protein upon
HU treatment was 35%, 57% or 37% (Figure 1C, lanes 2,
4 and 6, respectively) as compared to the untreated
controls. The fact that the rescue of hEXO1 degradation
observed in these experiments was partial might depend
on the potency of the shRNA to ATR, which appeared
to be less eﬀective than the one to ATM (Figure 1C).
Quantiﬁcation of the data indicated that the reduction of
protein expression was 75% for ATM and 55% for ATR.
In order to get a more deﬁnitive answer to the involvement
of ATR in the control of hEXO1 stability, we examined the
ATR-Seckel cell line. These cells carry a mutated ATR
allele that is transcribed in an mRNA undergoing incorrect
splicing (40). Nonetheless, ATR-Seckel cells maintain low
level of the correctly spliced mRNA for ATR (40) and in
the course of culturing, display increasing expression of
functional ATR (M. O’Driscoll and P. Jeggo, personal
communication). Such model appeared to be ideal to assess
the eﬀect of diﬀerential level of ATR on hEXO1 stability.
In this system, we observed that the expression of hEXO1
was higher in early- than in late-passage cells (Figure 1D,
compare lane 1 with lane 3), in a manner that was inversely
proportional to the level of expressed ATR. More
importantly, treatment of late-passage Seckel cells with
HU led to a clear decrease in the amount of hEXO1, an
eﬀect that did not occur in early passage cells (Figure 1D,
compare lane 4 with lane 2).
To ﬁnally conﬁrm the lack of involvement of ATM in
signaling to hEXO1, we examined the response of
ﬁbroblast derived from an AT-patient (33). Both in
ATM-deﬁcient and -proﬁcient ﬁbroblasts, hEXO1 dis-
played a similar pattern of degradation in response to HU
treatment (Figure 1E), thus ruling out a role for ATM in
this process. Taken together, these data show that the
stalled-fork signal was relayed to hEXO1 through an
ATR-dependent pathway.
Identification ofthe sitesof phosphorylation in hEXO1
Having established that hEXO1 was phosphorylated in
an ATR-dependent manner in response to stalled forks, we
set out to identify the sites of phosphorylation. To this end,
we ectopically expressed an Omni-tagged form of hEXO1
in HEK-293 cells. Large-scale immunoprecipitations
(Figure 2A) allowed us to obtain suﬃcient amount of
hEXO1 protein to perform LC-MS/MS analysis. In typical
experiments, we were able to cover >85% of hEXO1
sequence (Supplementary Figure 2). The results show
that hEXO1 was phosphorylated at nine residues (8 Ser,
1 Thr) under basal conditions and at three additional
sites (2 Ser, 1 Thr) upon HU treatment (Table 1, Figure 2B
and Supplementary Figure 2). The three HU-induced sites
of phosphorylation (S454,T 621 and S714) conformed to the
requirement for recognition by CHK1/CHK2, MAPK/
SAPK and ATM/ATR, respectively. These ﬁndings point
to the involvement of classic DNA damage signaling
pathways as well as stress-activated kinase cascades in
hEXO1 phosphorylation in response to HU. Among the
nine basal sites of phosphorylation, residues S376,S 598,S 623
and S639 conformed to the recognition by proline-directed
kinases (S/T-P), whereas residues T581 and S660 resembled
typical CK2 targets (S/T-X1–2-D/E). The sites S422 and S746
fulﬁlled the requirement for phosphorylation by CHK1/
CHK2 (-X-K/R-X2-S/T, where  is any hydrophobic
amino acid), or, as second choice, for CK2. Among the
basal sites of phosphorylation that we identiﬁed is S598,a
site that was previously described in a large-scale study on
HeLa cell nuclear phosphoproteome (41). A representative
MS-chromatogram for the identiﬁcation of phosphoryla-
tion at theHU-induced S714 site is shown in Supplementary
Figure 3.
Characterization of pS714 antibody
In order to monitor hEXO1 phosphorylation in response
to inhibition of DNA synthesis, we raised a rabbit
polyclonal antibody to pS714. This site is particularly
514 Nucleic Acids Research, 2008, Vol. 36, No. 2interesting because it fulﬁlls the requirements for recogni-
tion and phosphorylation by ATM/ATR protein kinases
and because its phosphorylation has been independently
conﬁrmed by large-scale mass spectrometry studies (42) in
the course of our work. To assess its speciﬁcity, the
antibody was tested on total cell extracts derived from
HeLa cells that ectopically expressed hEXO1 and were
either left untreated or treated with HU. The data indi-
cate that the pS714 antibody selectively detected phos-
phorylated hEXO1 from extracts of HU-treated cells
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Figure 1. ATR-dependent control of hEXO1 stability in response to stalled replication. (A) HEK-293, U2OS, HeLa and MEF cells were grown in
the presence or the absence of 2mM HU for 24h. Whole cell extracts were immunoprecipitated with the rabbit polyclonal antibody F-15 and
resolved on a 8% SDS–PAGE. Human and mouse EXO1 were visualized with the monoclonal antibody Ab-4. MSH6 and IgG(H) were used as
controls for the input and the quality of the immunoprecipitation, respectively. (B) Upper panels: immunoprecipitation of hEXO1 from HEK-293T
cells left untreated (lane 1) or treated for 8h with either 10mM KU-55933 (lane 2), 4mM caﬀeine (lane 3), 2mM HU (lane 4), 4mM caﬀeine followed
by 2mM HU (lane 5) or 10mM KU-55933 followed by 2mM HU (lane 6). hEXO1 was detected as described above. The signal given by IgG(H) was
used as control for the quality of the immunoprecipitation. Lower panels: western blot analysis of phosphorylated CHK1 in whole cell extracts was
used as read-out for the cellular response to HU. TFIIH was used as loading control. (C) HEK-293T cells were stably transfected with EV, ATR or
ATM shRNA constructs. hEXO1 was immunoprecipitated from cells left untreated or treated with HU for 16h. The signal given by IgG(H) was
used as control for the quality of the immunoprecipitation. ATR and ATM expression was monitored to assess the extent of downregulation by
shRNA. TFIIH served as loading control. The data shown represent one of three independent experiments. (D) ATR-Seckel cells at early or late
passages were either left untreated or treated with HU for 16h. hEXO1 was immunoprecipitated as described above. TFIIH and IgG(H) were used
as controls for the input and the quality of the immunoprecipitation, respectively. The expression of ATR was examined by western blot analysis. (E)
AT or AT+ATM ﬁbroblasts were treated in the presence or the absence of HU and the expression of hEXO1 was assessed following
immunoprecipitation as described above. TFIIH and IgG(H) were used as controls for input and quality of the immunoprecipitation, respectively.
Nucleic Acids Research,2008, Vol. 36,No. 2 515(Figure 3A, upper panel, lane 3), despite the reduction of
total hEXO1 amount induced by HU (Figure 3A, middle
panel, lane 3 versus lane 2).
To deﬁnitely assess whether the epitope recognized by
the antibody was phospho-S714, we ectopically expressed
wt-hEXO1 or the point mutant A714-hEXO1 in HEK293
cells that were either left untreated or treated with HU.
The results obtained show that the pS714 antibody could
detect the HU-induced increase in hEXO1 phosphoryla-
tion only in the case of wt-hEXO1 (Figure 3B, lane 3)
but not in the A714 point mutant (Figure 3B, lane 4).
This allowed us concluding that the pS714 antibody
speciﬁcally reacted with hEXO1 phosphorylated at S714.
Next, we examined the ability of the pS714 antibody
to detect endogenous hEXO1. To this end, immunopreci-
pitation experiments were performed on total extracts of
HEK-293T cells using either the pS714 antibody
(Figure 3C, upper panel) or antibody F15 (Figure 3C,
lower panel). The data show that antibody pS714 was able
to precipitate the phosphorylated form of the endogenous
hEXO1 protein and this occurred only in the case of
HU-treated cells (Figure 3C, lanes 2 and 3). The fact that a
higher amount of phosphorylated hEXO1 was precipitated
from MG-132 treated cells in comparison to untreated
cells (Figure 3C, upper panel, lane 3 versus lane 2),
conﬁrmed our early ﬁnding that hEXO1 degradation is
phosphorylation-dependent (32). Antibody pS714 was also
suitable for the detection of phosphorylated hEXO1 by
western blot analysis upon immunoprecipitation of the
endogenous protein. A weak but clear signal was observed
upon treatment with HU and the proteasome inhibitor
MG-132 to prevent hEXO1 degradation (Supplementary
Figure 4).
Finally, considering that S714 belongs to the S/T-Q type
of DNA damage sites, we asked whether S714 is speciﬁcally
phosphorylated upon replication fork stalling or if it is also
targeted in response to other types of DNA damage. To
this end, we treated HEK-293T cells ectopically expressing
Omni-tagged hEXO1 with either IR or HU. Detection of
hEXO1 with the pS714 antibody indicated that HU
potently induced phosphorylation at this site (Figure 3D,
A
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97
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200
++
66
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1 846
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Figure 2. Identiﬁcation of the sites of phosphorylation in hEXO1. (A) HEK-293 cells were transfected with EV (lane 3) or an expression vector
encoding Omni-hEXO1 (lanes 4–7). Cells were left untreated (lanes 4 and 5) or treated with 2mM HU for 24h (lanes 6 and 7). hEXO1 was
immmunoprecipitated with the Omni-probe antibody. Samples were subjected to 8% SDS–PAGE electrophoresis and the gel was stained with
Coomassie Brilliant Blue. Molecular weight protein markers (lane 1) and 500ng BSA (lane 2) were loaded to estimate the amount of
immunoprecipitated hEXO1. The protein bands corresponding to hEXO1 were excised from the gel and underwent LC-MS/MS analysis. (B)
Schematic representation of hEXO1 and localization of the sites of phosphorylation identiﬁed by LC-MS/MS. N-terminal (N) and internal (I)
catalytic domains are indicated. Dots, basal sites; stars, HU-induced sites.
Table 1. Sites of phosphorylation that were identiﬁed in hEXO1
phosphopeptides present among the peptides detected in LC–MS/MS
analysis
Phosphopeptide Phospho-site Treatment
HRNYpSPRPE Ser376 None
KRPRpSAELS Ser422 None
ATVFpTDEES Thr581 None
TRTIpSPPTL Ser598 None
SRTPpSPSPS Ser623 None
RKSDpSPTSL Ser639 None
SEESpSDDES Ser660 None
GACSpSQSQE Ser674 None
YKSSpSADSL Ser746 None
NKSLpSFSEV Ser454 HU
DSFRpTPSPS Thr621 HU
KLLDpSQSDQ Ser714 HU
516 Nucleic Acids Research, 2008, Vol. 36, No. 2lane 3), whereas the IR treatment was only minimally
aﬀecting phosphorylation at S714 (Figure 3D, lane 2).
Taken together, these results show that the pS714
antibody is able to speciﬁcally recognize the phosphory-
lated S714 epitope in hEXO1 and that S714 is a site
selectively targeted in response to stalled replication.
The pS714 antibody may be potentially employed to
monitor the ﬂow of signal transduction events in studies
on stalled DNA replication. A second foreseeable
application for this tool is the identiﬁcation of hEXO1
interacting proteins by means of combined immuno-
precipitation/mass spectrometry under conditions of
stalled DNA replication, when hEXO1 is phosphoryl-
ated at S714.
Mutation of thesites of phosphorylation andeffect on
hEXO1 protein stability
In order to assess the impact of phosphorylation on
hEXO1 protein stability, we generated single and multiple
Alanine point mutants of the sites of phosphorylation and
expressed them in HeLa cells. The data showed that single
mutation of the three HU-induced sites (A454,A 621 and
A714) did not rescue hEXO1 degradation in response to
HU (Figure 4A). Likewise, the double point mutants
A621,714 and A454,714 were as sensitive as wild-type hEXO1
to the eﬀect of HU (Figure 4B). On the contrary, the triple
mutant A454,621,714 was expressed to an apparently higher
level than wild-type hEXO1 and resulted to be less
sensitive to HU (Figure 4B). The higher basal stability
of the A454,621,714 mutant is unlikely to result from
constitutively increased expression (i.e. transcription and
translation) of this speciﬁc isoform as compared to other
point mutants. Such increased stability rather reﬂects
the fact that, although phosphorylation at the three
HU-induced sites might be substoichiometric under
basal conditions of cell growth, it is suﬃcient to trigger
continuous degradation of hEXO1. Support to this view
comes from the evidence that low level of phosphorylation
at S714 was detected with the pS714 antibody in exponen-
tially growing HEK-293T cells that were ectopically
expressing hEXO1 but were not treated with HU
(Figure 3B, upper panel, lane 2). As mentioned above,
we observed that the triple mutant A454,621,714 displayed
A
hEXO1
hEXO1-pS714
TFIIH
B
HU −−+
Omni-hEXO1-wt
Omni-hEXO1-A714
− ++
−−−
+
−
+
hEXO1-pS714
TFIIH
1234
HU − +
Omni-hEXO1-wt − + +
−
12 3
D
hEXO1
−−+
IR − + −
12 3
HU
CHK2-pT68
TFIIH
IP
WB
C
IP: hEXO1-pS714
IP: hEXO1
hEXO1
hEXO1
MG132 − +
HU − + +
−
IgG(H)
hEXO1-pS714
Figure 3. Characterization of the hEXO1-pS714 antibody. (A) HeLa cells were transfected with EV (lane 1) or Omni-hEXO1 expression vector (lanes
2 and 3). Cells were left untreated or treated with HU for 24h. Whole cell extracts were subjected to 8% SDS–PAGE electrophoresis, followed by
western blot analysis using antibody pS714 to detect phosphorylated hEXO1 (upper panel) or mouse monoclonal antibody Ab-4 to visualize the entire
pool of hEXO1 (middle panel). TFIIH served as control for equal loading. (B) HEK-293T cells were transfected with EV (lane 1), expression vector
for wild-type Omni-hEXO1 (lanes 2 and 3) or for the non-phosphorylatable mutant Omni-hEXO1-A714 (lane 4). Cells were treated with HU as
indicated. Western blot analysis of total cell extracts was performed using antibody pS714.( C) Immunoprecipitation of endogenous hEXO1 from
HEK-293T cells using either pS714 antibody (upper panel) or rabbit polyclonal antibody F-15 (lower panel) followed by western blot analysis with
mouse monoclonal antibody Ab-4. (D) HEK-293T cells were transfected with an expression vector for wild-type Omni-hEXO1 (lanes 1–3). Cells were
left untreated or treated with IR (10Gy) or HU (2mM), as indicated, and hEXO1 was immunoprecipitated using rabbit polyclonal antibody F-15
(upper panels). The signal given by IgG(H) was used as control for the quality of the immunoprecipitation. The phosphorylation status of hEXO1
and CHK2 was monitored by western blot analysis using phospho-speciﬁc antibodies (lower panels). TFIIH was used as loading control.
Nucleic Acids Research,2008, Vol. 36,No. 2 517increased resistance to HU-induced degradation as
compared to wt-hEXO1 (29.3 6.35% degradation for
the triple mutant versus 53.7 10.69% for the wild type,
Supplementary Figure 5). On the other hand, mutation of
all sites in a S/T-Q cluster (Supplementary Figure 2), did
not result in any signiﬁcant rescue of hEXO1 degradation
(Figure 4B). Taken together, these data indicate that the
HU-induced phosphorylation of hEXO1at the three
residues described in this study facilitated the destabiliza-
tion of the protein, though additional events may
contribute to hEXO1 degradation in response to fork
arrest. With regard to this point, it is worth considering
the possibility that ATR-dependent phosphorylation of
hEXO1 interacting partners, among which might be a
speciﬁc E3-ligase for hEXO1, could be of key importance
in the overall control of hEXO1 degradation in response
to stalled replication. Future experiments will aim at
clarifying this issue.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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